Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

소아 원외 요로감염 환아에서 분리된 E. coli에 대한 cefixime을 포함한 경구 항생제의 감수성 연구

Susceptibility tests of oral antibiotics including cefixime against Escherichia coli, isolated from pediatric patients with community acquired urinary tract infections

  • 이수영 (가톨릭대학교 의과대학 소아과학교실) ;
  • 이정현 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김종현 (가톨릭대학교 의과대학 소아과학교실) ;
  • 허재균 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김선미 (서울위생병원 소아과) ;
  • 마상혁 (마산파티마병원 소아과) ;
  • 강진한 (가톨릭대학교 의과대학 소아과학교실)
  • Lee, Soo Young (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Lee, Jung Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Jong Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Hur, Jae Kyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Sun Mi (Seoul SDA Hospital) ;
  • Ma, Sang Hyuk (Masan Fatima Hospital) ;
  • Kang, Jin Han (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 투고 : 2006.02.08
  • 심사 : 2006.03.28
  • 발행 : 2006.07.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : 최근 소아 요로감염의 가장 흔한 원인균인 E. coli에 대한 항생제 내성 문제가 점차 대두되고 있다. 본 연구에서는 소아 원외 요로감염 환아에서 분리된 E. coli에 대한 cefixime을 포함하여 흔히 사용되고 있는 경구용 항생제의 시험관 내 감수성 연구를 시행하여 적합한 치료 항생제 선택의 기초 자료를 얻고자 하였다. 방 법 : 2004년 10월부터 2005년 9월까지 연구 참여 병원 소아과 외래에서 요로감염으로 진단된 206명 환아의 요 배양검사에서 동정된 211개 균주 중 188개 E. coli를 대상으로 경구용 항생제(ampicillin, amoxillin, ampicillin-sulbactam, cefaclor, TMP-SMX, cefixime)에 대한 시험관 내 감수성 검사를 실시하였다. 결 과 : 분리된 E. coli 균주에 대한 항생제별 감수성 결과에서 내성률은 각각 ampicillin 81.4%, amoxicillin 85.6%, ampicillin-Sulbactam 77.2%, cefaclor 93.6%, TMP-SMX 50.5%, cefixime 13.3%이었다. ESBL 생성 E. coli는 7.0%이었다. 결 론 : Aminopenicillins계, cefaclor, sulfa약제들은 E. coli에 대한 내성률이 매우 높아 소아 요로감염의 일차 선택 항생제로 유용하지 못한 것으로 추정할 수 있었다. 그러나 cefixime과 같은 3세대 cephalosporin은 일차 치료 실패할 경우 이차 선택항생제로 유용할 수 있으며, 일차 선택 항생제로도 사용될 수 있을 것으로 추정되었다. E. coli의 항생제 내성 양상에 대한 광범위한 연구와 지속적 감시를 통하여 소아 원외 요로감염 치료에서 1차적으로 선택될 수 있는 경구용 항생제에 대한 지침 자료가 요구된다.

Purpose : Urinary tract infection(UTI) is one of the most frequent infections in children. E. coli is the most frequent etiological micropathogen in pediatric community UTI, and E. coli has developed resistance to many antibiotics, highlighting the need for regular surveys of this organism resistant patterns in the community. The aim of this study was to determine the oral antibiotic susceptibility patterns of E. coli, isolated from pediatric patients with uncomplicated community acquired UTI. Methods : E. coli isolates, obtained from pediatric patients with uncomplicated community acquired UTI between October in 2004 to September in 2005. And minimal inhibitory concentrations(MICs) of oral aminopenicillins and beta-lactamase inhibnitors(ampicillin, amoxacillin, ampicillin-sulbactam), oral cephalosporins(cefaclor, cefixime) and sulfa drug(trimethoprime-sulfamethoxazole) were performed according to the National Committee for Clinical Laboratory Standards(NCCLS) guide line. Results : Total 211 organisms were isolated from pediatric out-patients with community UTI. E. coli was the most common organism(89 percent), followed by E. fecalis, Proteus species, S. aureus, M. morganii, and P. aeruginosa. The resistant rates of aminopenicillins and beta-lactamase inhibitors, cefaclor and sulfa drug to E. coli were very high. But, the resistant rate of cefixime was markedly low, and ESBL strains were isolated with small rates. Conclusion : Our study results suggest that aminopenicillins, cefaclor and sulfa drug may not be useful as first line empirical antibiotics to treat pediatric patients with community UTI in Korea. But, 3rd generation cephalosporin such as cefixime can be used as effective second line antibiotics after primary treatment failure, also may be useful as an empirical first line antibiotic. Finally, we conclude that a continuous surveillance study to monitor susceptibility patterns of E. coli in community UTI will be needed for the standard guide lines of empirical oral antibiotic treatment.

키워드

과제정보

연구 과제 주관 기관 : 동아제약

참고문헌

  1. Hoberman A, Chao HP, Keller DM, Hickey R, Davis HW, Ellis D. Prevalence of urinary tract infection in febrile infants. J Pediatr 1993;123:17-23 https://doi.org/10.1016/S0022-3476(05)81531-8
  2. Bauchner H, Philipp B, Dashefsky B, Klein JO. Prevalence of bacteriuria in febrile children. Pediatr Infect Dis J 1987; 6:239-42 https://doi.org/10.1097/00006454-198703000-00004
  3. Hoberman A, Wald ER. Treatment of urinary tract infections. Pediatr Infect Dis J 1999;18:1020-1 https://doi.org/10.1097/00006454-199911000-00018
  4. Larcombe J. Urinary tract infection in children. BMJ 1999; 319:1173-5 https://doi.org/10.1136/bmj.319.7218.1173
  5. Goldraich NP, Manfroi A. Febrile urinary tract infection : Escherichia coli susceptibility to oral antimircobials. Pediatr Nephrol 2002;17:173-6 https://doi.org/10.1007/s00467-001-0808-8
  6. Russo TA, Johnson JR. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli : ExPEC. J Infect Dis 2000;181:1753-4 https://doi.org/10.1086/315418
  7. Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Eschericahia coli : focus on an increasingly important endemic problem. Microbes Infect 2003;5:449-56 https://doi.org/10.1016/S1286-4579(03)00049-2
  8. Garau J, Xercavins M, Rodriguez-carballeira M, Gomez- Vera JR, Coll I, Vidal D, et al. Emergence and dissenmination of quinolone-resistant Escherichia coli in the community. Antimicrobial Agents Chemother 1999;43:2736-41
  9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically approved standard. NCCLS document M7-6. Wayne, PA : National Committee for Clinical Laboratory Standards, 2003
  10. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001; 33:48-53 https://doi.org/10.1086/320873
  11. Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med 2001;345:1007-13 https://doi.org/10.1056/NEJMoa011265
  12. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community- acquired urinary tract infections. Ann Intern Med 2001;135:41-50 https://doi.org/10.7326/0003-4819-135-1-200107030-00012
  13. Burman WJ, Breese PE, Murray BE, Singh KV, Batal HA, MacKenzie TD, et al. Conventional and molecular epidemiology of Trimethoprim-Sulfamethoxazole resistance among urinary Escherichia coli isolates. Am J Med 2003;115:358- 64 https://doi.org/10.1016/S0002-9343(03)00372-3
  14. Manges AR, Dietrch PS, Riley LW. Mutidrug-resistant Escherichia coli clonal groups causing community-acquired pyelonephritis. Clin Infect Dis 2004;38:329-34 https://doi.org/10.1086/380640
  15. Roh JI, Kwon YS, Oh HK, Jeong JH, Ha MC, Jeong JY. A clinical and bacteriologic study of infants and children with urinary tract infection. J Korean Pediatr Soc 1991;34:57-65
  16. Cha YH, Choi HR, Jong SH, Ahn YM. A clinical study on urinary tract infection in infants and children. J Korean Pediatr Soc 1994;37:1488-99
  17. Oh SH. Antimicrobial treatment of pediatric urinary tract infection. Korean J Pediatr Infect Dis 2003;10:55-60 https://doi.org/10.14776/kjpid.2003.10.1.55
  18. Lee SY, Cho SH, Kim SM, Jeong DC, Chung SY, Lee KY, et al. Urinary tract infection in febrile infants with pyuria. Korean J Pediatr Infect Dis 2004;11:90-100 https://doi.org/10.14776/kjpid.2004.11.1.90
  19. Gold HS, Moellering RC Jr. Antimicrobial drug resistance. N Engl J Med 2003;335:1445-53 https://doi.org/10.1056/NEJM199611073351907
  20. Moon HW, Lee MA, Lee SJ. Risk factors for extendedspectrum ${\beta}$-lactamase producing Escherichia coli from children with urinary tract infections. Korean J Microbiol 2003;6:132-8
  21. Kim NH, Lee JA, Kim YK, Choi EH, Ha IS, Lee HJ, et al. Risk factors of urinary tract infections due to extendedspectrum ${\beta}$-lactamase producing Escherichia coil in children. Korean J Pediatr 2004;47:164-9
  22. Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999;104:79-86 https://doi.org/10.1542/peds.104.1.79
  23. Brogden RN, Campoli-Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989;38:524-50 https://doi.org/10.2165/00003495-198938040-00004
  24. Dogan R, Einhorn M, Lang R, Pomeranz A, Wolach B, Miron D, et al. Once daily cefixime compared with twice daily trimethoprim/sulfamethoxazole for treatment of urinary tract infection in infants and children. Pediatr Infect Dis J 1992;11:198-203 https://doi.org/10.1097/00006454-199203000-00005
  25. Gok F, Duzova A, Baskin E, Ozen S, Besbas N, Bakkaloglu A. Comparative study of cefixime alone versus intramuscular ceftizoxime followed by cefixime in the treatment of urinary tract infections in children. J Chemother 2001;13:277-80 https://doi.org/10.1179/joc.2001.13.3.277
  26. Ansbach RK, Dybus K, Bergeson R. Uncomplicated E coli urinary tract infection in college women : A follow-up study of E. coli sensitivities to commonly prescribed antibiotics. J Am Coll Health 2005;54:81-4 https://doi.org/10.3200/JACH.54.2.81-84